Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 2.0 Contact Hours.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca, Celgene Corporation, Daiichi Sankyo, Inc., Eisai, Exelixis, Inc., Genomic Health, Inc., Ferring Pharmaceuticals, Inc., Incyte Corporation, Jazz Pharmaceuticals, Novartis Pharmaceuticals Corporation, Novocure, Pfizer, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Regeneron, Seattle Genetics, Inc., Takeda Oncology, and Taiho Oncology, Inc.

Clinical Vignette Series: 36th Annual Chemotherapy Foundation Symposium (CFS®): Innovative Cancer Therapy for Tomorrow®


Release Date: January 31, 2019
Expiration Date: January 31, 2020
Media: Internet - based

Activity Overview

In Clinical Vignette Series: 36th Annual Chemotherapy Foundation Symposium (CFS®): Innovative Cancer Therapy for Tomorrow®, noted oncology thought leaders address clinical challenges that community oncologists, like you, face and offer their insight and commentary on the clinical application of new data and advances. This interactive, online activity features a series of case-based vignettes, self-reflection questions, and brief video clips in which the program faculty share their approaches and answer other related questions. This activity focuses on breast cancer, multiple myeloma, non–small cell lung cancer, and renal cell carcinoma and is based on content presented at the 2018 CFS® meeting. This annual gathering has a longstanding history of providing education, guidance, perspectives, and solutions to practicing oncologists. Delivering state-of-the-art cancer care requires incorporation of new clinical advances and data into practice. Across all cancer types, improvements in patient outcomes are being driven by novel approaches in testing, systemic therapy, targeted therapy and immunotherapies, and combination strategies. This online activity provides an unparalleled opportunity to learn new methods of optimizing and personalizing care for your patients with cancer.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca, Celgene Corporation, Daiichi Sankyo, Inc., Eisai, Exelixis, Inc., Genomic Health, Inc., Ferring Pharmaceuticals, Inc., Incyte Corporation, Jazz Pharmaceuticals, Novartis Pharmaceuticals Corporation, Novocure, Pfizer, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Regeneron, Seattle Genetics, Inc., Takeda Oncology, and Taiho Oncology, Inc.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  • At the end of the activity, educational content/audio files will be available for your reference.
  • In order to receive a CME/CE certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME/CE certificate upon completion of these steps.


Target Audience

This educational activity is directed toward oncologists, hematologists, nurses, nurse practitioners, and pharmacists interested in the treatment and management of patients with cancer. Radiotherapists, immunologists, fellows, physician assistants, researchers, case managers, and other healthcare professionals interested in the treatment of cancer are also invited to attend.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Determine the most appropriate testing strategies to identify molecular marker and treatment targets while stratifying risk to inform clinical decision making in cancer management
  • Describe key practice-changing clinical trial results that inform appropriate diagnostic and treatment approaches for patients with hematologic malignancies and solid tumors
  • Identify evidence-based immunotherapeutic, chemotherapeutic, and targeted treatment strategies to optimize clinical outcomes
  • Delineate implementation strategies for multidisciplinary teams to anticipate and proactively manage treatment-related toxicities

Faculty, Staff, and Planners' Disclosures

Faculty

Adam M. Brufsky
Adam M. Brufsky, MD, PhD
Professor of Medicine
Associate Chief, Division of Hematology/Oncology
Co-Director, Comprehensive Breast Cancer Center
Associate Director, Translational Investigation
University of Pittsburgh
Pittsburgh, PA

Disclosures: Consultant: Bioarray, Novartis, Roche, Eisai, Celgene, Lilly, Pfizer, Agendia, Genomic Health, NanoString Technologies, and Biotheranostics

Ajai Chari
Ajai Chari, MD
Associate Professor
Medicine, Hematology, and Medical Oncology
The Mount Sinai Hospital
New York, NY

Disclosures: Grant/Research Support: Array Biopharma, Celgene, Novartis, MIllennium/Takeda, Amgen, Janssen Oncology, Pharmacyclics; Consultant: Array Biopharma, Celgene, Novartis, Millennium/Takeda, Amgen, Janssen Oncology, Bristol-Myers Squibb

Robert A. Figlin
Robert A. Figlin, MD, FACP
Steven Spielberg Family Chair in Hematology Oncology
Professor of Medicine and Biomedical Sciences
Director, Division of Hematology/Oncology
Deputy Director, Integrated Oncology Service Line
Deputy Director, Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center
Los Angeles, CA

Disclosures: No disclosures to report

Benjamin P. Levy
Benjamin P. Levy, MD
Clinical Director of Medical Oncology
Johns Hopkins Sidney Kimmel Cancer Center
Sibley Memorial Hospital
Washington, DC

Disclosures: Consultant: AstraZeneca, Celgene, Merck, Eli Lilly, Genentech, and Takeda.

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.
 

PER Pulse™ Recaps

1 of 3
PER PulseTM Recap

The 36th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Online: Clinical Vignette Series is a series of short video interviews with faculty from the symposium, who address a variety of questions commonly faced by practicing community oncologists via discussion of clinical vignettes that were presented. The activity features case-based discussions on:

  • Therapeutic Decision-Making for Stage III Non-Small Cell Lung Cancer
    Benjamin Levy, MD
  • Therapeutic Decision-Making for Extensive-Stage Small Cell Lung Cancer
    Benjamin Levy, MD
  • Management of Metastatic Clear Cell Renal Cell Carcinoma
    Robert Figlin, MD
  • Management of Multiple Myeloma in the Posttransplant Setting
    Ajai Chari, MD
  • Treatment Planning for Triple-Negative Breast Cancer From the Neoadjuvant to the Metastatic Setting
    Adam Brufsky, MD, PhD

Throughout the activity, these physicians answer questions about their decisions for case management, and offer perspective and guidance on issues important to community-based physicians.
This first of 3 PER Pulse™ Recaps summarizing the program focuses on Dr. Levy’s answers to questions about frontline treatment for stage III non-small cell lung cancer (NSCLC). During his interview, Dr. Levy:

  • Discusses his approach for a 66-year-old woman, former smoker (30-pack-year history), who presented with dyspnea and cough. Imaging showed a left upper lobe mass, left mediastinal nodal involvement, and metastasis to a right hilar node. No distant metastases, right lung involvement, or pleural effusion was detected. She was diagnosed with stage IIIB NSCLC. Biopsy was consistent with adenocarcinoma histology. Molecular testing was negative for oncogenic drivers; programmed death ligand-1 (PD-L1) testing (with 22C3 anti‒PD-L1 antibody) showed an expression level of 10%. She underwent concurrent chemoradiation therapy (chemoRT) with cisplatin/etoposide and radiation therapy (60 Gy), and achieved a partial response.
  • Shares his perspective on a variety of issues, including treatment options outside of a clinical trial, use of consolidation immunotherapy (IO) for patients with an EGFR mutation or PD-L1 expression <1%, and future approaches for IO and targeted agents in patients with nonmetastatic NSCLC.



2 of 3
PER PulseTM Recap

The 36th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Online: Clinical Vignette Series is a series of short video interviews with faculty from the symposium, who address a variety of questions commonly faced by practicing community oncologists via discussion of clinical vignettes that were presented. The activity features case-based discussions on:

  • Therapeutic Decision-Making for Stage III Non-Small Cell Lung Cancer
    Benjamin Levy, MD
  • Therapeutic Decision-Making for Extensive-Stage Small Cell Lung Cancer
    Benjamin Levy, MD
  • Management of Metastatic Clear Cell Renal Cell Carcinoma
    Robert Figlin, MD
  • Management of Multiple Myeloma in the Posttransplant Setting
    Ajai Chari, MD
  • Treatment Planning for Triple-Negative Breast Cancer From the Neoadjuvant to the Metastatic Setting
    Adam Brufsky, MD, PhD

Throughout the activity, these physicians answer questions about their decisions for case management, and offer perspective and guidance on issues important to community-based physicians.
This second of 3 PER Pulse™ Recaps summarizing the program focuses on Dr. Figlin’s answers to questions about management of metastatic renal cell carcinoma (RCC). During his interview, Dr. Figlin:

  • Discusses his initial approach for a 52-year-old woman who was diagnosed with clear cell metastatic RCC. She was treated with sunitinib 50 mg per day on the 4-weeks-on and 2-weeks-off schedule. She remained on sunitinib for another 6 months, with continued slow but definitive progression. New pancreatic metastases are seen on imaging at 6 months, and the patient has lost 10 pounds in the last 5 months.
  • Reviews data from studies of immunotherapy and VEGF tyrosine kinase inhibitors (Figure)



3 of 3
PER PulseTM Recap

The 36th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Online: Clinical Vignette Series is a series of short video interviews with faculty from the symposium, who address a variety of questions commonly faced by practicing community oncologists via discussion of clinical vignettes that were presented. The activity features case-based discussions on:

  • Therapeutic Decision-Making for Stage III Non-Small Cell Lung Cancer
    Benjamin Levy, MD
  • Therapeutic Decision-Making for Extensive-Stage Small Cell Lung Cancer
    Benjamin Levy, MD
  • Management of Metastatic Clear Cell Renal Cell Carcinoma
    Robert Figlin, MD
  • Management of Multiple Myeloma in the Posttransplant Setting
    Ajai Chari, MD
  • Treatment Planning for Triple-Negative Breast Cancer From the Neoadjuvant to the Metastatic Setting
    Adam Brufsky, MD, PhD

Throughout the activity, these physicians answer questions about their decisions for case management, and offer perspective and guidance on issues important to community-based physicians.
This third of 3 PER Pulse™ Recaps summarizing the program focuses on Dr. Brufsky’s answers to questions about therapy for triple-negative breast cancer (TNBC). During his interview, Dr. Brufsky:

  • Discusses his approach toward a 53-year-old woman who presented with a 4-cm left breast mass. Biopsy revealed an estrogen receptor–negative, HER2-negative infiltrating ductal carcinoma. She has no other evidence of disease, and you plan on offering a neoadjuvant doxorubicin-plus-cyclophosphamide (AC) regimen. Genetic testing does not reveal a germline BRCA1/2 mutation (gBRCA1/2m).
  • Shares his perspectives on use of capecitabine for a partial response to neoadjuvant AC-paclitaxel.
  • Reviews his recommendations for frontline treatment for this patient upon metastatic progression of her disease that involves the lung and liver.
  • Discusses related issues, including clinical trial options, relevance of gBRCA1/2m status to first-line treatment selection for metastatic disease, and how approval of talazoparib is likely to impact his practice.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
      1
2345678
9101112131415
16171819202122
23242526272829
Filter By